
Please try another search
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Anthony A. Rosenberg | 70 | 2017 | Independent Chairman of the Board |
Nadim Ahmed | 55 | 2021 | President, CEO & Director |
Patrick A. Baeuerle | 66 | 2022 | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board |
Ronald Levy | - | 2023 | Member of Scientific Advisory Board |
David McDermott | - | 2023 | Member of Scientific Advisory Board |
Anthony W. Tolcher | - | 2023 | Member of Scientific Advisory Board |
Stephen W. Webster | 63 | 2020 | Independent Director |
Anne-Marie Martin | 52 | 2022 | Independent Director |
Bahija Jallal | 63 | 2023 | Member of Scientific Advisory Board |
Patricia LoRusso | - | 2023 | Member of Scientific Advisory Board |
David P. Ryan | 57 | 2022 | Independent Director |
David D. Meek | 61 | 2024 | Independent Director |
Mary T. Thistle | 64 | 2024 | Director |
Chaim Putterman | - | 2024 | Member of Scientific Advisory Board |
Mario Sznol | - | 2024 | Member of Scientific Advisory Board |
Ricardo Grieshaber-Bouyer | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review